Scarica l'app Stockscreener
46.69
1.41%
-0.67
Dopo l'orario di chiusura:
46.80
0.11
+0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$47.36
Aprire:
$47.39
Volume 24 ore:
9.93M
Relative Volume:
0.68
Capitalizzazione di mercato:
$95.02B
Reddito:
$47.64B
Utile/perdita netta:
$5.42B
Rapporto P/E:
17.49
EPS:
2.67
Flusso di cassa netto:
$13.09B
1 W Prestazione:
-1.37%
1M Prestazione:
-0.36%
6M Prestazione:
-18.15%
1 anno Prestazione:
+9.50%
Intervallo 1D:
$46.57
$47.39
Intervallo di 1 settimana:
$46.18
$48.35
Portata 52W:
$41.90
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.69 | 96.34B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
What analysts say about Bristol Myers Squibb Company stockExceptional financial outcomes - Autocar Professional
Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - Insider Monkey
FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa
FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan
Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative
What drives Bristol Myers Squibb Company stock priceRapid wealth multiplication - PrintWeekIndia
What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com
BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - Benzinga
Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters
Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace
Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters
Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga
Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters
How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest
Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg.com
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option - BioSpace
Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan
BROKERS’ NOTES: Buy Novo Nordisk, sell Bristol Myers Squibb - BusinessLIVE
Will Increased Expenses Affect Bristol Myers' Performance? - The Globe and Mail
Key facts about Nik Jhangiani, Diageo's new interim CEO - Reuters
Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer in Schizophrenia Treatment - TipRanks
Bristol-Myers Squibb’s New Alzheimer’s Study: A Potential Game Changer? - TipRanks
Is Bristol-Myers Squibb Still an Undervalued Biopharma Play? - AInvest
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? - Benzinga
Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Drug Development? - TipRanks
Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research - ACCESS Newswire
What To Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report - barchart.com
Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income? - Insider Monkey
Bristol-Myers Squibb stock holds steady as UBS maintains Neutral rating By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today - Yahoo Finance
Bristol-Myers Squibb’s Melanoma Study Completion: Market Insights - TipRanks
Bristol-Myers Squibb stock holds steady as UBS maintains Neutral rating - Investing.com India
Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout - Fierce Pharma
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.81%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):